Idoia Morilla

994 total citations
18 papers, 464 citations indexed

About

Idoia Morilla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Idoia Morilla has authored 18 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Physiology. Recurrent topics in Idoia Morilla's work include HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer survivorship and care (4 papers). Idoia Morilla is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer survivorship and care (4 papers). Idoia Morilla collaborates with scholars based in Spain, United Kingdom and Chile. Idoia Morilla's co-authors include Hugo Arasanz, Grazyna Kochan, David Escors, Lucía Teijeira, Ana Bocanegra, Ruth Vera, Miren Zuazo, G. Fernández-Hinojal, María José Lecumberri and María Jesús García-Granda and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Idoia Morilla

15 papers receiving 461 citations

Peers

Idoia Morilla

ONCOL

IMMUN

PRM

PHYSI

Lucía Teijeira Spain

Elizabeth Ahern Australia

Shinsuke Shiotsu Japan

Adi Kartolo Canada

Valentina Zanfagnin United States

Haocan Song United States

Yasuyoshi Sato Japan

Francisco Aparisi Spain

Pei‐Wei Huang Taiwan

Diego Kauffmann‐Guerrero Germany

Lucía Teijeira Spain

Idoia Morilla

400 ×1.1

ONCOL

211 ×1.2

IMMUN

100 ×0.8

PRM

45 ×1.0

13 ×0.3

PHYSI

Citations per year, relative to Idoia Morilla Idoia Morilla (= 1×) peers Lucía Teijeira

Countries citing papers authored by Idoia Morilla

Since Specialization

Citations

This map shows the geographic impact of Idoia Morilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Idoia Morilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Idoia Morilla more than expected).

Fields of papers citing papers by Idoia Morilla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Idoia Morilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Idoia Morilla. The network helps show where Idoia Morilla may publish in the future.

Co-authorship network of co-authors of Idoia Morilla

This figure shows the co-authorship network connecting the top 25 collaborators of Idoia Morilla. A scholar is included among the top collaborators of Idoia Morilla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Idoia Morilla. Idoia Morilla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Zambom-Ferraresi, Fabrício, Adrienne Castillo, Mauricio R. Delgado, et al.. (2024). Effects of an individualised exercise program in hospitalised older adults with cancer: A randomised clinical trial. The journal of nutrition health & aging. 29(1). 100424–100424.

Chocarro, Luisa, Hugo Arasanz, Leticia Fernández, et al.. (2022). CAR-T Cells for the Treatment of Lung Cancer. Life. 12(4). 561–561. 14 indexed citations

Arasanz, Hugo, Ana Bocanegra, Idoia Morilla, et al.. (2022). Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. Cancers. 14(16). 3846–3846. 26 indexed citations

Arasanz, Hugo, Miren Zuazo, Ana Bocanegra, et al.. (2021). Hyperprogressive Disease: Main Features and Key Controversies. International Journal of Molecular Sciences. 22(7). 3736–3736. 20 indexed citations

Martínez‐Velilla, Nicolás, Mikel L. Sáez de Asteasu, Robinson Ramírez‐Vélez, et al.. (2021). Multicomponent Exercise Program in Older Adults with Lung Cancer During Adjuvant/Palliative Treatment: A Secondary Analysis of an Intervention Study. The Journal of Frailty & Aging. 10(3). 247–253. 5 indexed citations

Arasanz, Hugo, Miren Zuazo, Ana Bocanegra, et al.. (2020). Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers. 12(2). 344–344. 58 indexed citations

Ramírez‐Vélez, Robinson, et al.. (2020). Effects of a Multicomponent Exercise Program in Older Adults with Non-Small-Cell Lung Cancer during Adjuvant/Palliative Treatment: An Intervention Study. Journal of Clinical Medicine. 9(3). 862–862. 11 indexed citations

Zuazo, Miren, Hugo Arasanz, G. Fernández-Hinojal, et al.. (2019). Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy. EMBO Molecular Medicine. 11(7). e10293–e10293. 143 indexed citations

Bocanegra, Ana, G. Fernández-Hinojal, Hugo Arasanz, et al.. (2019). PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. International Journal of Molecular Sciences. 20(7). 1631–1631. 62 indexed citations

10.

Pernas, Sònia, Anna Petit, Fina Climent, et al.. (2019). PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. Frontiers in Oncology. 9. 707–707. 15 indexed citations

11.

Stradella, Agostina, Idoia Morilla, Catalina Falo, et al.. (2019). Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. BMC Pharmacology and Toxicology. 20(1). 68–68. 7 indexed citations

12.

Ramírez‐Vélez, Robinson, Alejandro Lucía, Nicolás Martínez‐Velilla, et al.. (2019). Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer. Cancers. 11(7). 944–944. 88 indexed citations

13.

Pernas, Sònia, F. Climent, Laia Paré, et al.. (2018). Abstract P2-09-11: PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer. Cancer Research. 78(4_Supplement). P2–9.

14.

Gironés, Regina, Idoia Morilla, Carmen Guillén‐Ponce, et al.. (2017). Geriatric oncology in Spain: survey results and analysis of the current situation. Clinical & Translational Oncology. 20(8). 1087–1092. 10 indexed citations

15.

Gil‐Gil, Miguel, et al.. (2017). Efficacy of taxanes followed by anthracyclines as neoadjuvant therapy in HER2-negative breast cancer (BC): Analysis of everyday clinical practice.. Journal of Clinical Oncology. 35(15_suppl). e12112–e12112.

16.

Stradella, Agostina, Sònia Pernas, Noemí Vidal, et al.. (2016). Breast-GPA and type of treatment predictors of survival in brain metastasis patients.. Journal of Clinical Oncology. 34(15_suppl). e13530–e13530. 1 indexed citations

17.

Hernández, Berta, Maite Martínez, Lucía Teijeira, et al.. (2014). Crizotinib in advanced ALK-positive non-small cell lung cancer: Results of a retrospective cohort in Complejo Hospitalario de Navarra, Spain.. Journal of Clinical Oncology. 32(15_suppl). e19158–e19158. 2 indexed citations

18.

Verdaguer, Helena, Idoia Morilla, & Ander Urruticoechea. (2013). Eribulin Mesylate in Breast Cancer. Women s Health. 9(6). 517–526. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact